Key Points
- Insider sale: Elizabeth Lin sold 4,601 Tarsus Pharmaceuticals shares for $339,829.86 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 19.74% to 18,707 shares. She also sold an additional 6,977 shares the following day for $558,160.
- Stock and earnings: TARS recently traded at $83.21, near its 52-week high of $85.25. The company reported a quarterly loss of $0.43 per share, missing estimates, though revenue of $173.91 million exceeded expectations.
- Analyst and institutional sentiment: Analysts maintain a “Moderate Buy” consensus with an average price target of $90.50, while institutional investors own 90.01% of the stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $73.86, for a total value of $339,829.86. Following the transaction, the insider owned 18,707 shares in the company, valued at approximately $1,381,699.02. This represents a 19.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Elizabeth Yeu Lin also recently made the following trade(s):
- On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $127,200.00.
- On Wednesday, September 2nd, Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total value of $430,960.00.
Tarsus Pharmaceuticals Trading Up 0.5%
NASDAQ TARS opened at $83.21 on Friday. The firm has a market cap of $3.65 billion, a P/E ratio of -76.34 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The stock's 50-day moving average is $65.45 and its 200-day moving average is $65.75. Tarsus Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $85.25.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The business had revenue of $173.91 million for the quarter, compared to the consensus estimate of $169.65 million. Sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have weighed in on TARS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Guggenheim lowered their price objective on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research report on Tuesday, July 21st. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Mizuho cut their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $90.50.
Check Out Our Latest Stock Report on Tarsus Pharmaceuticals
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $242,705,000. Jupiter Topco LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth about $176,834,000. California State Teachers Retirement System grew its stake in Tarsus Pharmaceuticals by 5,971.9% in the 2nd quarter. California State Teachers Retirement System now owns 2,288,813 shares of the company's stock valued at $144,058,000 after buying an additional 2,251,118 shares during the last quarter. Deep Track Capital LP grew its stake in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company's stock valued at $178,290,000 after buying an additional 1,250,000 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at about $75,099,000. Institutional investors own 90.01% of the company's stock.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.
In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
